“…Psoriasis is a skin disease which has substantial socioeconomic bearing for several reasons: (1) it is a highly prevalent disease, affecting about 2–3% of adults in Western populations [1,2,3,4,5,6]; (2) it is a chronic disease which is associated with permanent or frequently recurring, highly visible and symptomatic skin lesions [7, 8]; (3) it leads to significant burden of disease and a reduction in quality of life (QoL) in patients from all countries [9,10,11,12]; (4) many patients with psoriasis are of working age, this results in work day loss, and therefore increased indirect costs (productivity losses). …”